LYRA · Lyra Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $25.0K | $183.0K | $183.0K | - | $195.0K | $598.0K | $532.0K | - | $544.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $4.05M | $5.11M | $4.88M | - | $5.90M | $13.26M | $18.24M | - | $12.37M |
| SG&A | - | $2.24M | $3.50M | $3.26M | - | $3.93M | $5.14M | $5.82M | - | $5.00M |
| Total Operating Expenses | - | $6.26M | $9.01M | $9.02M | - | $12.64M | $49.57M | $24.06M | - | $17.37M |
| D&A | - | $100.0K | $200.0K | $128.0K | - | - | - | $136.0K | - | - |
| Operating Income | - | ($6.24M) | ($8.83M) | ($8.84M) | - | ($12.44M) | ($48.97M) | ($23.52M) | - | ($16.83M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | $3.0K | $2.0K | $4.0K | - | $7.0K | $12.0K | $14.0K | - | $16.0K |
| Net Income | - | ($5.98M) | ($7.44M) | ($8.55M) | - | ($11.87M) | ($48.13M) | ($22.45M) | - | ($15.65M) |
| EPS - Basic | - | ($3.38) | ($5.51) | ($6.50) | - | ($9.00) | ($37.00) | ($17.50) | - | ($13.50) |
| EPS - Diluted | - | ($3.38) | ($5.51) | ($6.50) | - | ($9.00) | ($37.00) | ($17.50) | - | ($13.50) |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.89M | $22.05M | $29.78M | $31.73M | $40.58M | $23.80M | $31.91M | $15.80M | $22.35M | $24.85M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $663.0K | $627.0K | $680.0K | $725.0K | $1.18M | $2.29M | $4.97M | $2.84M | $3.13M | $5.05M |
| Current Assets | $16.27M | $23.02M | $31.06M | $33.91M | $43.02M | $54.44M | $69.44M | $89.44M | $104.82M | $104.92M |
| Total Assets | $36.11M | $43.71M | $52.57M | $56.32M | $66.35M | $78.76M | $94.58M | $141.53M | $142.60M | $120.58M |
| Current Liabilities | $9.52M | $9.48M | $11.16M | $11.47M | $12.63M | $14.95M | $19.28M | $18.72M | $19.60M | $19.23M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $46.83M | $48.04M | $50.95M | $52.44M | $54.75M | $58.14M | $63.60M | $64.02M | $53.18M | $36.34M |
| Stockholders' Equity | ($10.72M) | ($4.33M) | $1.62M | $3.87M | $11.59M | $20.62M | $30.98M | $77.50M | $89.42M | $84.24M |
| Retained Earnings | ($433.71M) | ($426.76M) | ($420.77M) | ($413.34M) | ($404.79M) | ($393.81M) | ($381.94M) | ($333.81M) | ($311.36M) | ($296.20M) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($8.84M) | - | - | - | ($22.45M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | $7.86M | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - | $8.64M | - | - |
| CapEx | - | - | - | - | - | - | - | $2.15M | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | ($24.60M) | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | -24948.0% | -4823.0% | -4831.1% | - | -6380.5% | -8189.6% | -4421.8% | - | -3093.2% |
| EBITDA margin | - | -24548.0% | -4713.7% | -4761.2% | - | - | - | -4396.2% | - | - |
| Net margin | - | -23936.0% | -4063.9% | -4670.5% | - | -6088.7% | -8048.7% | -4220.3% | - | -2877.0% |
| Free cash flow margin | - | - | - | - | - | - | - | -4624.8% | - | - |
| FCF / Net income | - | - | - | - | - | - | - | 1.10 | - | - |
| R&D / Revenue | - | 16188.0% | 2792.3% | 2664.5% | - | 3026.7% | 2218.1% | 3428.2% | - | 2273.5% |
| SG&A / Revenue | - | 8944.0% | 1913.1% | 1783.1% | - | 2015.9% | 859.4% | 1093.6% | - | 919.7% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -13.7% | -14.1% | -15.2% | - | -15.1% | -50.9% | -15.9% | - | -13.0% |
| Return on equity | - | 138.3% | -458.5% | -220.7% | - | -57.6% | -155.4% | -29.0% | - | -18.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.71 | 2.43 | 2.78 | 2.96 | 3.41 | 3.64 | 3.60 | 4.78 | 5.35 | 5.45 |
| Quick ratio | 1.71 | 2.43 | 2.78 | 2.96 | 3.41 | 3.64 | 3.60 | 4.78 | 5.35 | 5.45 |
| Cash ratio | 1.67 | 2.33 | 2.67 | 2.77 | 3.21 | 1.59 | 1.66 | 0.84 | 1.14 | 1.29 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -3.37 | -10.10 | 32.41 | 14.54 | 5.72 | 3.82 | 3.05 | 1.83 | 1.59 | 1.43 |
| Liabilities / Assets | 1.30 | 1.10 | 0.97 | 0.93 | 0.83 | 0.74 | 0.67 | 0.45 | 0.37 | 0.30 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.01 | 0.00 | - | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 7.4x | 107.2x | - | 40.8x | 29.2x | 256.9x | - | 132.2x |
| P / S | - | 461.5x | 66.0x | 2269.2x | - | 4313.4x | 1514.4x | 37420.2x | - | 20467.7x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -87.2% | -69.4% | -65.6% | - | -64.2% | 30.6% | 29.8% | - | 51.5% |
| Revenue CAGR (3y) | - | -58.9% | -23.4% | -67.6% | - | 140.6% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 49.9% | 82.0% | 62.4% | - | 26.1% | -196.8% | -35.9% | - | -13.5% |
| Net income growth (YoY) | - | 49.6% | 84.5% | 61.9% | - | 24.1% | -208.2% | -38.1% | - | -6.0% |
| EPS growth (YoY) | - | 62.4% | 85.1% | 62.9% | - | 33.3% | -10177.8% | -3877.3% | - | -3275.0% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | -54.8% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -94.8% | -95.0% | -87.0% | -75.5% | -68.6% | 17.3% | 10.7% | -9.6% |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Lyra Therapeutics against the 5 most active filers in the same SIC group.